Where does SK Bioscience Co., Ltd. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), SK Bioscience Co., Ltd. ranks #25,232 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does SK Bioscience Co., Ltd. hold?

SK Bioscience Co., Ltd. holds 11 US utility patents granted between 2021 and 2025, spanning 8 technology areas.

What is SK Bioscience Co., Ltd.'s Innovation Score?

SK Bioscience Co., Ltd. has an Innovation Score of 49.1 out of 100 (top 15% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does SK Bioscience Co., Ltd. focus on?

SK Bioscience Co., Ltd.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 11 patents, ranking #1,740 of 6,058 assignees active in that subclass. Grants appear in 8 CPC subclasses total.

Is SK Bioscience Co., Ltd.'s patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for SK Bioscience Co., Ltd..

What does claim depth mean for SK Bioscience Co., Ltd.'s patents?

SK Bioscience Co., Ltd.'s patents average 17.4 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the SK Bioscience Co., Ltd. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

SK Bioscience Co., Ltd.

USPTO PatentsView assignee record - 11 granted patents across 8 technology areas, recorded in grant years 2021–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, SK ranks #25,232 of 49,997 tracked US assignees by granted-patent volume, with 11 patents across 8 technology areas.

#25,232
of 49,997 US assignees by volume: Top 15%
by Innovation Score (49.1/100): 17.4
avg claims per patent

USPTO PatentsView assignee plate

Corpus R25232 · Foreign Corporation #25,232 · 11 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · SPAN-YRS · BOOK-RICH

GRANTS-MICRO 11 grants
MID-PACK #25,232/49,997
PHOTO-FINISH Simbionix
CPC-NARROW A61P · 8 areas
INNOV-PAR 49.1/100
CLAIMS-RICH 17.4 claims/avg
TYPE-FRNCORP Foreign Corp
SPAN-YRS 2021–2025 · 5y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: Simbionix Ltd. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How SK’s 49.1 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 8.6 pts (18%) Velocity 20.0 pts (41%) Breadth 10.0 pts (20%) Claim depth 10.5 pts (21%)

Qualcomm Incorporated · highest

85
SK Bioscience · this assignee

49
3D Lighting… · lowest

7

What this shows SK's Innovation Score is 49.1/100 (top 15% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for SK?

Each dot is one of SK’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). SK’s own 17.4 claims/patent is ABOVE the 16.9 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

SK vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where SK's grants concentrate

SK Bioscience Co., Ltd. is a focused PatentsView assignee: 8 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2024 (4 grants) versus a trough of 2 in 2021. By volume, SK sits between Simbionix Ltd. and Smartcells, Inc..

SK's three-year grant acceleration

SK Bioscience Co., Ltd. shows 6 grants in 2022–2024 against only 2 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Simbionix

11
Singapore Aerospa…

11
Singulex

11
Sinopsys Surgical

11
Skyhawk Therapeut…

11
Skystream

11
SL Mirrortech

11
Smartcells

11
SK Bioscience ◀

11

What this shows SK holds 11 patents at rank #25,164, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near SK

By rank, the assignees closest to #25,164 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in SK's primary technology class.

SK's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

49 Top 15% higher than 85% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2021–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2021–2019 baseline. Full figures in the table below.

View data table

SK Bioscience Co., Ltd. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2021	2	18.2%
2022	2	18.2%
2024	4	36.4%
2025partial year	3	27.3%

Which technologies does SK Bioscience Co., Ltd. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 11

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 10

C07K - Peptides 8

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 4

C12R - Indexing Scheme Associated With Subclasses C12c - C12q, Relating TO Microorganisms 3

Y02A - Technologies FOR Adaptation TO Climate Change 2

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 1

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 1

Top 8 of 8 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

SK Bioscience Co., Ltd.'s patent record in context - here's where to go next.

SK Bioscience Co., Ltd.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 100% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #25,232 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare SK Bioscience Co., Ltd. against Simbionix Ltd., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 49.1/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.